antigens and <10% positive for the CD3 antigen. When membrane Ig could be detected, monoclonality could be demonstrated on the basis of monotypic light chain expression .
Reagents. mAbs mouse mAb OKT3 (anti-CD3 antigen) and OKM5 were purchased from Ortho Diagnostic Systems Inc. (Raritan, NJ) . The Bl and B4 mAb (anti-CD20 and CD19 antigens, respectively) were obtained from Coulter Immunology (Margency Andilly, France) . The Leu-1 mAb (anti-CD5) was from Becton Dickinson & Co. (Mountain View, CA) ; the IOT14 (anti-a chain of the IL-2-R CD25) was provided by Immunotech (Marseille Luminy, France). mAb25 (19) (anti-CD23 antigen) was used at 5 pg/ml final dilution . Insolubilized rabbit antibody specific for human w chain (anti-u antibody) was purchased from Bio-Rad Laboratories (Richmond, CH). FITC-conjugated F(ab')z fragment of goat anti-mouse Ig was from Tago Inc . (Burlingame, CA) .
Factors. rIL-2 was a gift of Biogen (SA, Geneva, Switzerland). The preparation used had an estimated activity of 10' U/mg protein and contained 97 .3% IL-2 by SDS-PAGE analysis . IL-4 was obtained from Dr. K . Arai (DNAX Research Institute, Palo Alto, CA) as supernatants from L cells transfected with the peD or PEBT vector containing the human cDNA clone (13) . Some experiments were performed with highly purified L cell-derived IL-4 . A unit of IL-4 was defined as described previously (14) . We verified the biological activity of these IL-4 preparations on normal human B cells ; when used at 50-100-U/ml concentrations, they proved able to induce the expression of the CD23 marker, and to enhance DNA synthesis in the presence of anti-Ii antibody (data not shown) . A mock preparation consisting of culture supernatants of L cells transfected with a nonrelated cDNA was also used . Recombinant human IFN-y was obtained from Roussel Uclaf (Romainville, France) . The preparation had a specific activity of 10' U/mg protein.
Cell Preparations . B-CLL cells were purified as follows . Mononuclear cells were isolated from the blood of B-CLL patients by centrifugation on a Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) gradient . T cells were eliminated by two cycles of rosetting using aminoethylisothiouronium bromide-treated sheep red blood cells . These preparations were analyzed using a FAGS TAR flow cytometer. They were homogeneous small cells, contained <0 .5% cells labeled by the OKT3 and by the OKM5 antibodies, and were devoid of activation markers (17) .
B Cell Proliferation Assay. Cells (10 5 ) were cultured in flat-bottomed microtest tissue culture plates (Falcon Labware, Oxnard, CA) in 0 .2 ml RPMI-1640 culture medium supplemented with 1 % L-glutamine, 1 % antibiotics, 2-ME (0 .5 x 10 -5 M), and 2 % FCS. The B cell growth was assayed in two different systems. In the one-step assay, B cells were cultured for 3 d with anti-g antibody (7 ug/ml) in the presence of IL-2 or IL-4 . In the two-step assay, B cells were cultured alone for 24 and 48 h with IL-2, IL-4, and with both interleukins. Cells were extensively washed and cultured with factors for 3 additional days . Cells were pulsed with 0 .5 PCi of [3 Hlthymidine (CEA, Saclay, France) during the last 16 h of culture period, and incorporation of [3Hlthymidine was measured by a standard liquid scintillation counter. Cultures were performed in duplicate and the results were expressed as the mean of counts per minute per culture . All experiments were performed at least two times, and data shown were from one representative experiment .
Fluorescence Analysis. Cells were cultured for 24 h with various factors and washed twice before staining. 0 .5 x 106 viable cells were treated with antibody at the appropriate dilution in PBS containing 2 % BSA and a 0 .1 % sodium azide (PBSS/BSA/azide) . After a 30-min incubation at 4°C, the cells were washed twice in cold PBS/BSA/azide, resuspended in 50 pl of 1/10 dilution of FITC-conjugated goat F(ab')z anti-mouse Ig, and incubated for 30 min at 4°C . Thereafter, the cells were washed twice in PBSIBSA/azide and resuspended in PBS/2 % formaldehyde . Fluorescence analysis was performed on a FRCS TAR flow cytometer. The response was assessed on day 3 and expressed as cpm . t In these experiments purified IL-4 was used . S Cells were cocultured with anti-p antibody (7 pg/ml) and the indicated amounts of interleukins, expressed as final U/ml for IL-4 and IL-2 and as final dilutions for mock (these dilutions corresponded to that of 50 and 10 U/ml of IL-4, respectively) .
did IL-4 stimulate DNA synthesis in these conditions . These negative results were obtained with IL-4 concentrations up to 100 U/ml . Data from six representative patients among responders and nonresponders to IL-2 are presented in Table I . The same data were obtained when the response was measured on day 6 (data not shown).
In another series ofexperiments, B-CLL cells from three patients were preincubated with anti-p antibody for 2 d, separated from the insolubilized anti-g antibody, and cultured for 3 additional days with the same interleukins . Again, IL-4 did not enhance DNA synthesis. The response of anti-g-activated cells was 1,180 f 237 cpm in the presence of 100 U/ml of IL-4 as compared with 858 t 170 cpm in the absence of interleukin. The same anti-g-activated cells did respond to IL-2: 17,327 t 2,545 cpm. In one additional patient we verified that a 2-d preculture of B cells with IL-4 (50 U/ml) did not enhance the response to anti-g antibody in a second-step incubation (data not shown) . IL-4 Inhibits the Response to IL-2. We then tested whether IL-4, although devoid FIGURE 1 . IL-4 profoundly suppresses the response to IL-2. In the presence of anti-It antibody cells were cultured with IL-2 (50 U/ml), in the absence or in the presence of IL-4 (50 U/ml) . Cultures from patients 1, 3, 4, and 5 were performed with purified IL-4. A cpm was calculated on day 3 . of effect in itself, might interfere with the responsiveness of B-CLL lymphocytes to IL-2 . Cells from the 10 patients responding to costimulation by anti-P antibody and IL-2 were selected. They were cultured for 3 d with anti-p antibody and IL-2 (50 U/ml) in the absence or presence of 50 U/ml of IL-4 ( Fig. 1) . In all instances, IL-4 profoundly inhibited the response to IL-2 (mean suppression: 90 t 2%). These results were obtained with a purified preparation of IL-4 in four patients (patients 1, 3, 4, and 5) as well as a crude preparation (the six other patients). The mock preparation had no inhibitory effect in the six patients tested (mean suppression: 3%).
In three patients (patients 3, 4, and 9) the dose-effect curve of IL-4 was established . B-CLL lymphocytes were stimulated with anti-p, antibody and 50 U/ml of IL-2, and the effects of various concentrations of IL-4 were determined (Fig. 2) . The 50% inhibitory concentration of IL-4 corresponded to 1.5 U/ml. An identical result was obtained when the inhibitory effect of IL-4 was assayed in the presence of 5 U of IL-2 (data not shown) .
In the same experiments DNA synthesis was measured on day 6 in order to verify that IL-4 would not delay the response to IL-2. IL-4 inhibited the day 6 response to the same extent as the day 3 response (data not shown) . It should be pointed Cells from patient 11 were cultured in the presence of IFN-'Y (1,000 U/ml) or anti-p antibody (7 pg/ml) . DNA synthesis was measured on day 3 . Purified IL-4 was used .
out that IL-4 profoundly suppressed the response to IL-2, regardless of its magnitude, even when this response was low (see Fig. 1 ). In the same line we verified that IL-4 did not enhance the response to costimulation with anti-g antibody and IL-2 in cells from patients unresponsive to IL-2. The cells from patients 2 and 6 (see Table  I ) were costimulated with anti-j antibody and IL-2 in the absence or presence of IL-4. Their marginal response to IL-2 was not enhanced by IL-4 (data not shown) . The Inhibitory Effect ofIL-4 Is Observed in the Absence ofAnti-u Antibody. The previously described experiments were performed in the presence of anti-P antibody as this reagent is required to obtain an optimal response to IL-2 in most cases of B-CLL. However, in some cases IL-2 alone is able to support DNA synthesis. The cells from three patients meeting this criteria were selected in order to examine the interaction between IL-2 and IL-4 in the absence of other stimulants. Cells from these patients were stimulated with IL-2 alone (50 U/ml) in the absence or presence of 50 U/ml of IL-4. As shown in Table II , IL-2 did stimulate DNA synthesis in these cells and this response was fully inhibited by IL-4. In the same conditions the supernatants of 10-d cultures from these patients were examined for the presence of Ig. In no instance was Ig detected, regardless of the presence of IL-4. We verified that IL-4 did not affect cell viability. At the end of a 6-d culture of B-CLL cells, the recovery of viable cells (evaluated by Trypan blue exclusion) was determined and expressed as percent of the initial cell input. In the presence of IL-2 (50 U/ml) alone FIGURE 3. The simultaneous presence of IL-2 and IL-4 is necessary for inhibition. Cells from patient 8 were pretreated for 48 h (they axis) with medium, 50 U/ml of IL-2, or 50 U/ml of purified IL-4. Cellswere washed and cultured for3 additional days . Cultures were performed with IL-2 (50 U/ml), IL-4 (50 U/ml), or both interleukins .
the recovery of viable cells was 73%, to be compared with 80% in the presence of IL-2 (50 U/ml) and IL-4 (50 U/ml). IL-4 Inhibits the Costimulation by Interferon-y and IL-2. We previously showed (20) that IFN-y, although in our hands unable to support DNA synthesis by B-CLL cells, can in some patients enhance the responsiveness to IL-2 . We thus tested whether IL-4 could inhibit the costimulation ofB-CLL cells by IL-2 and IFN-y. In the presence of IFN-y (1,000 U/ml) or anti-tt antibody, B-CLL cells were cultured with IL-2, IL-4, and with both interleukins for 3 d. As shown in Table III , in the presence of IL-4 the response to IL-2 and IFN-y was suppressed to the same extent as that to IL-2 and anti-g antibody.
IL-4 Can Deliver a Positive Signal to B-CLL Cells. One of the most clear-cut early effects of IL-4 on resting B lymphocytes is the upregulation of the expression of CD23 antigen (16) . We thus wondered whether IL-4 was able to exert such an effect on B-CLL cells. The cells from patient 8 were selected as they expressed a low, and potentially upregulation-susceptible, percentage of CD23 + cells (Table IV) . A 24-h incubation of these cells with IL-4 alone induced a twofold increase in the number of CD23 + cells. This effect of IL-4 was observed regardless of the presence of IL-2. Thus, these two interleukins did not interact for the expression of CD23 . Similarly IL-4 did not affect the enhancement of CD25 antigen by IL-2. The cells from patient 8 were able to respond to IL-2 in the absence of anti-g antibody (see Table  II ). We could thus verify that both effects of IL-4 (on CD23 expression and on the response to IL-2) could take place in the same monoclonal cells. After preincubation with IL-4, these cells were extensively washed and cultured with IL-2 alone or in the concomitant presence of IL-2 and IL-4 (Fig. 3) . Again, IL-4 suppressed the response to IL-2. It should be pointed out that the continuous presence of IL-4 was required for this inhibition to take place: cells pretreated by IL-4 and cultured with IL-2 alone were fully able to respond to this interleukin. We also verified that pretreatment with IL-2 did not prevent the suppressive effect of IL-4 (Fig. 3, bottom) . Discussion IL-4 is an interleukin with pleiotropic effects, acting on multiple targets among immunocompetent cells (21) . Whether used alone or in combination with another signal, IL-4 is able to positively affect several aspects of the B cell response . In view of the heterogeneity of the B cell response patterns to IL-4, we decided to analyze the effects of this interleukin on monoclonal B cells, obtained from B-CLL patients . These cells can respond to several interleukins. They are considered as frozen at a given differentiation step and could thus exhibit a dissociated responsiveness to some of the effects of IL-4 . They probably arise from a discrete subpopulation of normal B cells of which they may be representative .
One o£ the most conspicuous effects of Il-4 on human as well as murine B cells is the enhancement of anti-Ft-induced DNA synthesis (1, 14) . In a first series of experiments we tested whether this effect could be demonstrated on B-CLL cells. Negative results were obtained with cells from 12 different patients even at IL-4 concentrations up to 100 U/ml . We verified that this lack of response was not due to a delayed peak of DNA synthesis and was not associated with a terminal differentiation . This unresponsiveness was apparent in two-step incubation experiments, regardless of the reagent used initially. It could not be attributed to the inefficiency of the signal provided by anti-p antibody, as cells from 10 patients did respond to costimulation with IL-2 and anti-p antibody. Thus, in contrast to normal polyclonal B cells, B-CLL cells do not respond to anti-p antibody and IL-4 by an increased DNA synthesis. This could be linked to the malignant transformation or could indicate a different responsiveness of the normal B cell subset from which B-CLL cells arise.
IL-2 is able to enhance DNA synthesis by cells from most B-CLL patients (17, 22, 23) . Moreover, in selected patients the effects of this interleukin can be enhanced by IFN-y (22) and/or IFN-a (18) . Thus, monoclonal B cells provide suitable targets to search for synergy between interleukins. We examined the interactions between IL-4 and IL-2 . IL-4 profoundly and constantly suppressed the response to IL-2 in all patient responders to this interleukin . This effect was obtained with low concentrations of IL-4 with a 50% inhibitory concentration of 1.5 U/ml . It was not observed with mock preparations of IL-4, and this effect could be demonstrated with a preparation of IL-4 purified to homogeneity. It was not attributable to a delayed DNA synthesis and did not result in terminal differentiation .
These results indicated a negative interaction between IL-4 and IL-2 itself. Indeed they could be obtained in three different experimental conditions : (a) When an optimal response to IL-2 was obtained by costimulation with anti-A antibody ; (b) when IL-2 was used alone, in these B-CLL cells able to respond to this interleukin in the absence of first signal (17) ; and (c) when a synergistic response to IL-2 and IFN-y (20) took place. This latter result is important in view of the previously reported interaction between IFN-y and IL-4 (14, 16) .
This negative interaction between IL-4 and IL-2 was unexpected in view of the synergy between these interleukins on T cell proliferative response (15) . However, it fits with two recently published sets of data . IL-4 inhibits the development of cytotoxic effector cells that occurs in response to IL-2 (24) . IL-4 inhibits the growth of bone marrow-derived pre-B cells (12) . As discussed earlier, B-CLL lymphocytes might be representive of a minor normal B lymphocyte population exhibiting an unusual responsiveness to IL-4 . This is supported by the observation that IL-4, although able to enhance DNA synthesis by normal polyclonal B cells, partially suppresses the IL-2-dependent proliferation of these cells (Defrance, T., et al ., manuscript submitted for publication) .
Another early effect of IL-4 on normal resting B cells is the upregulation of the expression of CD23 (16, 25, 26) . We thus examined whether this effect could take place in B-CLL lymphocytes. To address this question we selected cells from one patient on the basis of the following criteria : (a) These cells expressed low levels of CD23 and were thus potentially susceptible to upregulation ; and (b) these cells were responsive to IL-2 in the absence of anti-p antibody, allowing the study of the interaction between both interleukins. The incubation with IL-4 induced an upregulation of CD23, showing that IL-4 could positively act on these monoclonal B cells. This contrasted with the profound negative effect of IL-4 on the proliferative response of the same cells to IL-2 . The relationships between these two effects of are not yet understood . The preincubation of B-CLL cells with IL-4 neither prevents their subsequent responsiveness to IL-2 (provided IL-4 is removed) nor interferes with the upregulation of CD25 expression by IL-2 itself (see Table IV 
